早期脓毒性休克:血管加压药还是液体
该随机对照试验纳入急诊就诊的成人脓毒性休克患者1000例,随机分为限制液体量并早期使用血管加压药组(血管加压药组)与较多液体量并延迟使用血管加压药组(液体组),干预至少6小时、至多24小时。主要终点为随机化至第90天存活且出院的天数。血管加压药组与液体组第90天存活且出院天数中位数均为76天(差值0.0天,95%CI -2.7至2.7,P=1.00)。两组不良事件发生率相似,但肺水肿发生率血管加压药组0.6% vs 液体组5.0%(P<0.001)。
要点
- 急诊成人脓毒性休克中,限制液体早期升压组与较多液体延迟升压组第90天存活且出院天数中位数均为76天(差值0.0天,95%CI -2.7至2.7,P=1.00)。
- 随机化后24小时内血管加压药组静脉液体量较液体组少(中位差值-1108 ml,95%CI -1395至-850)。
- 血管加压药组接受血管加压药的患者比例较液体组高18.9个百分点(95%CI 13.3至24.5)。
- 肺水肿发生率血管加压药组0.6% vs 液体组5.0%(P<0.001),其余不良事件两组相似。
- 该策略未增加90天存活出院天数,但限制液体早期升压可减少肺水肿。
适用人群与场景
- 急诊就诊的成人脓毒性休克患者。
处置流程与药物剂量
- 血管加压药组:限制液体量并早期使用血管加压药,干预至少6小时、至多24小时。
- 液体组:较多液体量并延迟使用血管加压药,干预至少6小时、至多24小时。
研究设计与关键结果
- 研究类型:随机对照试验;样本量:1000例随机化,意向性治疗人群963例(血管加压药组481例,液体组482例);人群:急诊就诊的成人脓毒性休克患者。
- 干预与对照:血管加压药组(限制液体量+早期血管加压药)vs 液体组(较多液体量+延迟血管加压药),干预至少6小时、至多24小时。
- 主要终点:第90天存活且出院天数中位数血管加压药组76天(四分位距55至83)vs 液体组76天(四分位距55至82),差值0.0天(95%CI -2.7至2.7,P=1.00)。
- 关键次要终点:随机化后24小时内血管加压药组静脉液体量较液体组少(中位差值-1108 ml,95%CI -1395至-850);血管加压药组接受血管加压药的患者比例较液体组高18.9个百分点(95%CI 13.3至24.5)。
- 不良事件:肺水肿发生率血管加压药组0.6% vs 液体组5.0%(P<0.001),其余不良事件两组相似。
证据类型、等级与局限
- 证据类型:随机对照试验;局限:原文未报告局限性。
对床旁实践的改变
- 对于急诊成人脓毒性休克患者,限制液体量并早期使用血管加压药与较多液体量并延迟使用血管加压药相比,第90天存活且出院天数无差异。
- 限制液体早期升压策略可降低肺水肿发生率(0.6% vs 5.0%,P<0.001)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The optimal approach to early resuscitation in septic shock is unknown. Equipoise exists between the use of larger volumes of intravenous fluids to restore perfusion and the use of early vasopressor therapy along with smaller volumes of fluids to minimize potential harm from excess fluid.
METHODS: We randomly assigned adult patients who presented to the emergency department with septic shock to receive either fluids at restricted volumes and early vasopressor therapy (vasopressor group) or higher volumes of fluids and later vasopressor therapy (fluids group) for at least 6 hours and up to 24 hours. The primary outcome was days alive and out of the hospital from randomization to day 90.
RESULTS: A total of 1000 patients underwent randomization, with 499 assigned to the vasopressor group and 501 to the fluids group. Informed consent was not obtained for 37 patients, which left 963 patients in the intention-to-treat population (481 in the vasopressor group and 482 in the fluids group). Three patients in the fluids group were lost to follow-up for the primary outcome. In the first 24 hours after randomization, patients in the vasopressor group received less intravenous fluid than those in the fluids group (median difference, -1108 ml; 95% confidence interval [CI], -1395 to -850). The percentage of patients who received vasopressors was higher by 18.9 percentage points (95% CI, 13.3 to 24.5) in the vasopressor group. The median number of days alive and out of the hospital at day 90 was 76 (interquartile range, 55 to 83) in the vasopressor group and 76 (interquartile range, 55 to 82) in the fluids group (difference, 0.0 days; 95% CI, -2.7 to 2.7; P = 1.00). Adverse events occurred in similar percentages of patients in the two groups, except for pulmonary edema (0.6% in the vasopressor group vs. 5.0% in the fluids group; P<0.001).
CONCLUSIONS: Among adult patients who presented to the emergency department with septic shock, an approach that involved restricted fluid volume and early vasopressors did not result in a greater number of days alive and out of the hospital at day 90 than an approach involving greater fluid volume and later administration of vasopressors. (Funded by the Australian National Health and Medical Council Medical Research Future Fund and the New Zealand Health Research Council; ARISE FLUIDS ClinicalTrials.gov number, NCT04569942.).
参考来源
- Peake SL, Macdonald SPJ, Howe BD, et al. Vasopressors or Fluids in Early Septic Shock. N Engl J Med. 2026. PMID: 42274006. doi:10.1056/NEJMoa2516225
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。